title: 2-deoxy-2-((18)F)fluoro-D-glucose positron emission tomography/computed tomography imaging in paediatric oncology.
abstract: Positron emission tomography (PET) is a minimally invasive technique which has been well validated for the diagnosis, staging, monitoring of response to therapy, and disease surveillance of adult oncology patients. Traditionally the value of PET and PET/computed tomography (CT) hybrid imaging has been less clearly defined for paediatric oncology. However recent evidence has emerged regarding the diagnostic utility of these modalities, and they are becoming increasingly important tools in the evaluation and monitoring of children with known or suspected malignant disease. Important indications for 2-deoxy-2-((18)F)fluoro-D-glucose (FDG) PET in paediatric oncology include lymphoma, brain tumours, sarcoma, neuroblastoma, Langerhans cell histiocytosis, urogenital tumours and neurofibromatosis type I. This article aims to review current evidence for the use of FDG PET and PET/CT in these indications. Attention will also be given to technical and logistical issues, the description of common imaging pitfalls, and dosimetric concerns as they relate to paediatric oncology.
authors.affiliation: John Freebody, Eva A Wegner, Monica A Rossleigh, Department of Nuclear Medicine and PET, The Prince of Wales and Sydney Children's Hospitals, Randwick, NSW 2031, Australia.
authors.forename: John
authors.initials: J
authors.lastname: Freebody
authors.affiliation: John Freebody, Eva A Wegner, Monica A Rossleigh, Department of Nuclear Medicine and PET, The Prince of Wales and Sydney Children's Hospitals, Randwick, NSW 2031, Australia.
authors.forename: Eva A
authors.initials: EA
authors.lastname: Wegner
authors.affiliation: John Freebody, Eva A Wegner, Monica A Rossleigh, Department of Nuclear Medicine and PET, The Prince of Wales and Sydney Children's Hospitals, Randwick, NSW 2031, Australia.
authors.forename: Monica A
authors.initials: MA
authors.lastname: Rossleigh
keywords: Computed tomography; Dosimetry; Fluorodeoxyglucose F18; Oncology; Paediatrics; Positron emission tomography; Technical issues